Can you explain how you know CHF will be lucrative? (i.e. cost of treatment, number of treatments... likely commercial uptake). GVHD treatment is worth every cent, it provides a cure for life. Phase 2 CHF didn't provide the miracle LV remodelling and increases in ejection fraction that was hoped, It only showed beneficial in a surrogate end point of MACE in a small subset. Its health economics, no one will pay big money (over one hundred thousand dollars probably) for a treatment that doesn't provide for a long disease free period. The placement of an implantable defibrillator in the same population (at much less cost) provides far greater benefit.
Can you explain how you know CHF will be lucrative? (i.e. cost...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |